FDA Clears Pluvicto for Earlier Use in Metastatic Prostate Cancer

The U.S. Food and Drug Administration has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for adults with a form of advanced prostate cancer that has spread beyond the prostate. The new approval covers patients whose tumors are positive for prostate-specific membrane antigen, or PSMA, and whose disease still responds to hormone therapy. Under the new indication, Pluvicto is used alongside an androgen receptor pathway inhibitor, a standard type of hormone-based cancer medicine.

Pluvicto is a targeted radioligand therapy. It binds to PSMA on cancer cells and delivers a radioactive dose directly to the tumor cells, damaging their DNA. Before treatment, patients must have a scan to confirm that their cancer is PSMA-positive; those with PSMA-negative disease are not eligible.

The approval is based on the PSMAddition study of 1,144 adults with PSMA-positive metastatic prostate cancer. Participants received either Pluvicto plus standard hormone therapy or standard hormone therapy alone. The Pluvicto group had a 28% lower risk of cancer progression or death, measured by imaging, than the hormone therapy-only group. Overall survival results were not final when these findings were reported. Severe side effects occurred in roughly half of patients taking Pluvicto, including low blood cell counts and serious kidney problems.

Pluvicto is given intravenously once every six weeks for up to six doses. Because the treatment is radioactive, patients are advised to drink fluids and urinate often, limit close contact with others for two days after a dose, and avoid close contact with children and pregnant women for seven days. Common side effects include fatigue, dry mouth, nausea, and low blood counts. The drug can also cause temporary or permanent male infertility, and men with partners who can become pregnant must use birth control during treatment and for 14 weeks after the last dose.

Advertisement

What the PSMAddition Data Change for Prostate Cancer Treatment

A broader, earlier line of treatment

This approval moves targeted radiation into metastatic hormone-sensitive disease, where hormone therapy is the backbone. The practical effect is a larger pool of eligible patients and a new option at a point when the disease is still responding to hormonal treatment. The 28% figure is a relative risk reduction in progression or death; it signals clinically meaningful delay in disease worsening, but the source does not provide the absolute event rates needed to translate that into how many extra months of control an individual patient might expect.

PSMA testing becomes the gatekeeper

Because the drug only works against PSMA-positive cells, diagnosis now includes a molecular imaging step. That should help direct the drug to patients most likely to benefit, but it also adds a requirement for specialized imaging and expert interpretation. Health systems with limited access to PSMA scans may struggle to turn the approval into rapid routine use.

The safety burden is not trivial

Severe side effects in about half of treated patients, the need for regular blood monitoring, and radiation precautions after each dose make this a logistically demanding treatment. The safety profile is consistent with earlier Pluvicto experience, but low blood counts and kidney injury require active management. Because overall survival data are not yet final, patients and clinicians are weighing a progression benefit against a known toxicity burden.

What the approval does not answer

The source release does not address cost, reimbursement, manufacturing capacity, or how quickly treatment centers will be able to deliver the therapy. These factors will determine how widely the earlier approval translates into real-world use, particularly outside major oncology centers.

Advertisement

What Patients and Families Should Discuss After the Pluvicto Approval

For patients, caregivers, and clinicians considering Pluvicto, the approval raises several practical points to clarify:

  • Confirm with the oncology team whether a PSMA scan is appropriate and whether the tumor is PSMA-positive, since only PSMA-positive patients qualify.
  • Ask how the once-every-six-weeks schedule, the maximum of six doses, and the two-day and seven-day radiation contact limits fit into daily life.
  • Discuss how blood counts and kidney function will be monitored, because severe side effects occurred in about half of trial participants.
  • If fertility is a concern, ask about the risk of temporary or permanent infertility and the required contraceptive period of 14 weeks after the last dose.
  • Check insurance coverage, prior authorization requirements, and the nearest treatment center offering PSMA-guided therapy, because the approval itself does not address cost or access.